Clinical trials
Phase 1 Glomerulonephritis, IGA trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
17 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2021 | 1 |
| 2022 | 1 |
| 2023 | 2 |
| 2025 | 6 |
| 2026 | 6 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Recruiting | 7 |
| Completed | 4 |
| Not yet recruiting | 3 |
| Active, not recruiting | 1 |
| Enrolling by invitation | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| The Children's Hospital of Zhejiang University School of Medicine | 5 |
| Jiangsu HengRui Medicine Co., Ltd. | 2 |
| Air Force Military Medical University, China | 1 |
| Chengdu Suncadia Medicine Co., Ltd. | 1 |
| Grit Biotechnology | 1 |
| Guangdong Hengrui Pharmaceutical Co., Ltd | 1 |
| Hansoh BioMedical R&D Company | 1 |
| Jieyang People's Hospital | 1 |
| Nanjing Bioheng Biotech Co., Ltd. | 1 |
| Peking University First Hospital | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Glomerulonephritis, IGA | 17 |
| Autoimmune Diseases | 5 |
| Nephrotic Syndrome | 5 |
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 4 |
| Scleroderma, Systemic | 3 |
| Glomerulonephritis, Membranous | 2 |
| Anti-Glomerular Basement Membrane Disease | 1 |
| Glomerulosclerosis, Focal Segmental | 1 |
| Hemoglobinuria, Paroxysmal | 1 |
| Hepatitis, Autoimmune | 1 |
Trials
Showing 1 to 17 of 17. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.